Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03220009
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:08.350837+00:00
Published At
2018-10-03T00:00:00+00:00
Record Updated At
2018-10-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cervical Carcinoma", "Esophageal Carcinoma", "Mucosal Melanoma", "Mucosal Melanoma of the Head and Neck", "Oral Cavity Mucosal Melanoma", "Recurrent Melanoma", "Stage II Vulvar Cancer AJCC v7", "Stage III Vulvar Cancer AJCC v7", "Stage IIIA Vulvar Cancer AJCC v7", "Stage IIIB Vulvar Cancer AJCC v7", "Stage IIIC Vulvar Cancer AJCC v7", "Stage IV Oral Cavity Cancer AJCC v6 and v7", "Stage IV Vulvar Cancer AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVC Oral Cavity Cancer AJCC v6 and v7", "Vaginal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-10-03"
protocolSection.identificationModule.nctId
"NCT03220009"
protocolSection.identificationModule.officialTitle
"A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma"
protocolSection.statusModule.overallStatus
"WITHDRAWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Cervical Carcinoma (protocolSection.conditionsModule.conditions)
  • Esophageal Carcinoma (protocolSection.conditionsModule.conditions)
  • Mucosal Melanoma (protocolSection.conditionsModule.conditions)
  • Mucosal Melanoma of the Head and Neck (protocolSection.conditionsModule.conditions)
  • Oral Cavity Mucosal Melanoma (protocolSection.conditionsModule.conditions)
  • Recurrent Melanoma (protocolSection.conditionsModule.conditions)
  • Stage II Vulvar Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage III Vulvar Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Vulvar Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Vulvar Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Vulvar Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Oral Cavity Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Vulvar Cancer AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Oral Cavity Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Oral Cavity Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Stage IVC Oral Cavity Cancer AJCC v6 and v7 (protocolSection.conditionsModule.conditions)
  • Vaginal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.